- Pin
- Not sure how to use your Gate Post Growth Points? We've got you covered!
Growth Points Lucky Draw Round 1️⃣ 1️⃣ is coming soon!
Post, comment, like, and join chats daily to earn more Growth Points and win amazing prizes!
➡️ https://www.gate.io/post
🔥 This round features upgraded prizes — with surprise rewards waiting for you!
For more Growth Points tasks, tap the Growth Points icon next to your Gate Post avatar.
Thank you for your support and engagement — we’re here to reward your every effort!
#CommunityGrowthPoints#
- ⏰ Just a Few Days Left!
🔥 The 12th Anniversary Celebration is Ending Soon — Don’t Miss Your Chance to Claim Rewards
🚀 Limited-Time Revelry #5 is Live
👉 Log in & play to win iPhone 16 Pro, MacBook Air and more: https://www.gate.com/activities/12th-anniversary
🏆 Draw for merch & send greetings on the Greeting Wall to win exclusive merch prizes
More Details: https://www.gate.com/announcements/article/44624
#Gate12Years#
- 🔥 Gate Post Ambassador Exclusive Posting Reward Task Round 2 Is On! 🏆 Round 1 winners will be announced on May 26!
Sign up now 👉 https://www.gate.com/questionnaire/6722
Registration Period 🕙 May 23, 03:00 AM – May 26, 04:00 PM UTC
✍️ Post daily from May 26 to June 1 and share a $300 prize pool based on your post quality!
🎁 Reward Details:
S-Level Weekly Ranking Reward
Post every day for 7 days with an overall quality score above 90 to qualify for S-Level.
2 outstanding ambassadors will each receive a $50 trading fee rebate voucher.
A/B-Level Tiered Rewards
Based on the number of posts and
- 🎉 #Gate Post# Hits 50,000 Followers!
✨ To celebrate this amazing milestone, we're giving back to our incredible community!
🎁 4 Lucky Winners Will Each Receive $10 Points!
Join:
1️⃣ Follow Gate_Post
2️⃣ Like this post
3️⃣ Drop your congratulations in the comments!
End at 18:00, May 25 (UTC)
Fuhong Hanlin: Grants Alvogen Korea exclusive license for Hans.
Jin10 Data reported on April 25 that Fuhong Hanlin announced that the company has entered into a licensing protocol with Alvogen Korea Co., Ltd., granting it exclusive rights to commercialize Hanshuang (Srilumab injection) in South Korea. Under the protocol, Alvogen Korea will pay an upfront payment of $5 million, with regulatory milestone payments not exceeding $9.5 million, commercial sales milestone payments not exceeding $97.5 million, and tiered royalties calculated based on annual net sales ranging from 18% to 25%. The licensing protocol will take effect from the date of signing and will initially last until the 10th anniversary of the first commercial sale of the licensed product.